Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Daniel N Wolfe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Servic…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Rho Federal, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
In response to the coronavirus disease 2019 (COVID-19) pandemic, vaccines were quickly and successfully developed and deployed, saving millions of lives globally. While first-generation vaccines are safe and effective in preventing disease caused by SARS-CoV-2, next-generation vaccines have the potential to improve efficacy and safety. Vaccines delivered by a mucosal route may elicit greater protective immunity at respiratory surfaces, thereby reducing transmission. Inclusion of viral antigens in addition to the spike protein may enhance protection against emerging variants of concern. Next-generation vaccine platforms with a new mechanism of action may necessitate efficacy trials to fulfill regulatory requirements. The Biomedical Advanced Research and Development Authority (BARDA) will be supporting Phase 2b clinical trials of candidate next-generation vaccines. The primary endpoint will be improved efficacy in terms of symptomatic disease relative to a currently approved COVID-19 vaccine. In this paper, we discuss the planned endpoints and potential challenges to this complex program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA.
- Rho, Incorporated, Federal Research Operations, Durham, NC, USA.
- Tunnell Government Services, Berwyn, Pennsylvania, USA.
- Department of Medicine and Pediatrics, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
- Shabas Solutions, Fairfax, Virginia, USA.
ORCID-Profile: Daniel N Wolfe
Förderung
- Rho Federal
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Wolfe, D. N., Arangies, E., David, G. L., Armstrong, B., Scocca, T. Z., Fedler, J., Natarajan, R., Zhou, J., Jayashankar, L., Donis, R., Nesin, M., Meissner, H. C., Lemiale, L., Kovacs, G. R., Rele, S., Mason, R., & Cao, H. (2024). Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae286
Vancouver
Wolfe DN, Arangies E, David GL, Armstrong B, Scocca TZ, Fedler J, et al. Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae286
BibTeX
@article{Wolfe2024,
author = {Wolfe, Daniel N and Arangies, Elizabeth and David, Gloria L and Armstrong, Brian and Scocca, Theresa Z and Fedler, Janel and Natarajan, Ramya and Zhou, James and Jayashankar, Lakshmi and Donis, Ruben and Nesin, Mirjana and Meissner, H Cody and Lemiale, Laurence and Kovacs, Gerald R and Rele, Shyam and Mason, Robin and Cao, Huyen},
title = {Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae286}
}
EUVIMED